RWP
VIVO

RWA Wealth Partners’s Meridian Bioscience Inc VIVO Stock Holding History

RWA Wealth Partners’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-844
Closed -$13K – 746
2018
Q2 		$13K Buy
+844
New +$12.6K ﹤0.01% 588

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RWA Wealth Partners's VIVO Position: Q3 2018 in Review

RWA Wealth Partners sold out of Meridian Bioscience Inc (VIVO) in Q3 2018, closing a stake of 844 shares — an estimated $13K sold.

RWA Wealth Partners first reported a position in VIVO in Q2 2018 and held it in 1 quarter. The position peaked at $13K in Q2 2018. 177 funds tracked by Wall St. Rank hold VIVO as of Q3 2018.

  • RWA Wealth Partners reported no remaining Meridian Bioscience Inc position as of Q3 2018 after selling out during the quarter.
  • RWA Wealth Partners sold 844 Meridian Bioscience Inc shares in Q3 2018, an estimated $13K.
  • RWA Wealth Partners first reported a position in Meridian Bioscience Inc in Q2 2018 and held it in 1 quarter.
  • RWA Wealth Partners's Meridian Bioscience Inc position peaked at $13K in Q2 2018.
  • 177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2018.

Based on RWA Wealth Partners's 13F filing for Q3 2018, filed 14 Nov 2018.